Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in ÎçÒ¹¸£Àû1000¼¯ºÏ) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
ÎçÒ¹¸£Àû1000¼¯ºÏ
Woman with Alzheimer's starts conversing again after taking psilocybin
News
Life
New-to-science spider builds trap that flings ants into the air
News
ÎçÒ¹¸£Àû1000¼¯ºÏ
How menopause radically changes the brain – and what happens after
Features
Mind
‘Fusogenic’ neurosurgery let paralysed pigs walk again – are we next?
Comment
Popular articles
Trending New Scientist articles
1
How menopause radically changes the brain – and what happens after
2
Woman with Alzheimer's starts conversing again after taking psilocybin
3
We've found a mysterious substance on Titan and Pluto
4
Faecal transplant makes the brains of old mice act young again
5
New-to-science spider builds trap that flings ants into the air
6
‘Fusogenic’ neurosurgery let paralysed pigs walk again – are we next?
7
A quantum state that lasts forever may finally be within our grasp
8
How I used psychology to come back from the worst year of my life
9
A promising natural technique to remove CO2 could backfire
10
Fully autonomous drones have killed human soldiers for the first time
